These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 39234328

  • 1. Re: Efficacy and Safety of Vildagliptin and Remogliflozin as Add-on Therapy to Metformin in Patients of Type 2 Diabetes Mellitus.
    Raza H, Bhutta ME, Siddique MH.
    Sultan Qaboos Univ Med J; 2024 Aug; 24(3):418-419. PubMed ID: 39234328
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
    Mikhail N.
    Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Translating science into clinical practice: focus on vildagliptin in combination with metformin.
    Barnett AH.
    Diabetes Obes Metab; 2009 May; 11 Suppl 2():18-26. PubMed ID: 19385980
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.
    Pan C, Xing X, Han P, Zheng S, Ma J, Liu J, Lv X, Lu J, Bader G, Institution Investigators.
    Diabetes Obes Metab; 2012 Aug; 14(8):737-44. PubMed ID: 22369287
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Islet enhancer vildagliptin: a powerful partner with metformin for the treatment of patients with type 2 diabetes.
    Scherbaum WA.
    Diabetes Obes Metab; 2009 May; 11 Suppl 2():1-2. PubMed ID: 19385977
    [No Abstract] [Full Text] [Related]

  • 12. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.
    Göke R, Gruenberger JB, Bader G, Dworak M.
    Curr Med Res Opin; 2014 May; 30(5):785-9. PubMed ID: 24328429
    [Abstract] [Full Text] [Related]

  • 13. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.
    Bolli G, Dotta F, Colin L, Minic B, Goodman M.
    Diabetes Obes Metab; 2009 Jun; 11(6):589-95. PubMed ID: 19515179
    [Abstract] [Full Text] [Related]

  • 14. [Preclinical and clinical findings of the dipeptidyl peptidase-4 inhibitor vildagliptin].
    Ito H, Wajima T, Yamaguchi M, Mimori N, Sekiguchi K.
    Nihon Yakurigaku Zasshi; 2010 Nov; 136(5):299-308. PubMed ID: 21079371
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
    Schweizer A, Dejager S, Bosi E.
    Diabetes Obes Metab; 2009 Aug; 11(8):804-12. PubMed ID: 19476473
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients.
    Mudher Mikhael E.
    J Diabetes Res; 2016 Aug; 2016():6962574. PubMed ID: 27642611
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Vildagliptin and vildagliptin/metformin: new drug. Same limited efficacy as sitagliptin in type 2 diabetes.
    Prescrire Int; 2008 Oct; 17(97):188. PubMed ID: 19534040
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.